Related Experiment Video
Updated: Dec 12, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
RAF1 Gene Fusions as a Possible Driver Mechanism in Rare BAP1-Inactivated Melanocytic Tumors: A Report of 2 Cases
Michele Donati1,2, Petr Martinek2,3, Liubov Kastnerova2,3
1Department of Pathology, University Hospital Campus Bio-Medico, Rome, Italy.
Abstract:
BRCA1-associated protein (BAP1)-inactivated melanocytic tumor (BIMT) is a group of epithelioid melanocytic neoplasms characterized by the loss of function of BAP1, a tumor suppressor gene located on chromosome 3p21. They occur sporadically or in the setting of an autosomal-dominant cancer susceptibility syndrome that predisposes to the development of different internal malignancies. Most of these cutaneous lesions are associated with a BRAF-mutated melanocytic nevus and therefore are included in the group of combined nevi in the last WHO classification of skin tumors. Apart from a BRAF mutation, an NRAS mutation has been reported in rare cases, whereas in some lesions no driver mutation has been detected. Here, we report 2 cases of BIMTs with a BAP1 mutation and a RAF1 fusion. Both lesions proved to be BRAF and NRAS wild type and were associated with a conventional melanocytic nevus with dysplastic junctional features. We suggest that RAF1 fusions can represent an underlying driver genetic event in these cases. Our study extends the morphological and molecular spectrum in BIMTs.
Insights
BRCA1-associated protein (BAP1)-inactivated melanocytic tumors (BIMTs) can have RAF1 fusions, not just BRAF mutations. This finding expands the known genetic landscape of these rare skin neoplasms.
Area of Science:
- Oncology
- Dermatology
- Genetics
Background:
- BRCA1-associated protein (BAP1)-inactivated melanocytic tumor (BIMT) are rare epithelioid melanocytic neoplasms.
- BIMTs are characterized by BAP1 tumor suppressor gene loss-of-function.
- These tumors can occur sporadically or as part of a hereditary cancer syndrome.
Observation:
- Most BIMTs are associated with BRAF-mutated melanocytic nevi.
- Previous studies reported BRAF or NRAS mutations, or no driver mutation.
- This study identified RAF1 fusions in two BIMT cases.
Findings:
- The two reported BIMTs had BAP1 mutations and RAF1 fusions.
- These lesions were wild type for BRAF and NRAS mutations.
- The tumors were associated with conventional melanocytic nevi with dysplastic junctional features.
Implications:
- RAF1 fusions may represent a driver genetic event in a subset of BIMTs.
- This expands the known molecular spectrum of BIMTs.
- Understanding these genetic alterations is crucial for diagnosis and potential therapeutic strategies.
More Related Videos
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Ras Gene
Ras is a...
Abnormal Proliferation
MAPK Signaling Cascades
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...

